comprising as much as 83% of all hemodialysis accesses
Methods. Tissue samples were collected from the graft-vein [3] . The current one-year primary patency rate for PTFE anastomosis of stenotic PTFE grafts during surgical revision. dialysis grafts is 40 to 50%, with a two-year patency rate Specimens were graded using standard light microscopy and of approximately 25% [4, 5] . Graft thrombosis is the immunohistochemistry for the magnitude of neointimal hypercause of 80% of all vascular access dysfunction, and in plasia and for the expression of specific cell types, cytokines, and matrix proteins.
over 90% of thrombosed grafts, the underlying pathology
Results. VNH was characterized by the (1) presence of is a stenosis either at the venous anastomotic site or in the smooth muscle cells/myofibroblasts, (2) accumulation of extradownstream (proximal) vein [6] . Despite the enormity of cellular matrix components, (3) angiogenesis within the neothis problem, however, there are currently no effective intima and adventitia, and (4) presence of an active macrointerventions for either the prevention or treatment of phage cell layer lining the PTFE graft material. Platelet-derived venous stenosis in PTFE dialysis grafts [7, 8] . This is growth factor (PDGF), basic fibroblast growth factor (bFGF), probably caused by a lack of knowledge about the pathoand vascular endothelial growth factor (VEGF) were expressed physiology underlying venous stenoses in PTFE grafts, by smooth muscle cells/myofibroblasts within the venous neoespecially at a cellular and molecular level [7] . intima, by macrophages lining both sides of the PTFE graft, and by vessels within the neointima and adventitia.
Few studies have attempted to analyze the pathology aimed at these specific mediators and processes may be successis a significant amount of angiogenesis within these speciful in reducing the very significant human and economic costs mens [10] .
of vascular access dysfunction.
(PDGF) [14] , vascular endothelial growth factor (VEGF)
Molecules analyzed [15] , and ECM proteins [16] . However, it is not clear The expression of the following cell types, cytokines, that the mechanisms ascribed to arterial injury also apply and matrix proteins was analyzed in our samples. , and a macrokines and matrix proteins were chosen based on their phage marker (PGM-1) were used in this study. We putative involvement in other vascular injury syndromes chose to examine expression of these cell types in view [11, 12] . Identification of the mediators present in these of the important role they played in other models of failed grafts may provide insight into potential therapeuvascular injury [11] . Of note, SMA and desmin are differtic targets for venous stenosis in PTFE dialysis grafts.
entiation markers for cells of a smooth muscle cell phenotype [18, 19] .
Cytokines. The expression of PDGF-B, bFGF, and METHODS VEGF was analyzed based on their documented role Patients in the pathogenesis of arterial neointimal hyperplasia Clinical information was available on 7 of the 11 pa- [11, 20] . tients in our study. Within these constraints, the mean Matrix/structural proteins. Collagen IV, fibronectin, age of our patients was 62.6 years (range 41 to 85). Six tenascin, and laminin are all ECM proteins. Except for were African American, and one was Caucasian. Six tenascin, their counter-receptors belong to the integrin out of seven were male. Type II diabetes mellitus (four family of molecules. ECM proteins play a key role in patients), hypertension (two patients), and nonrecovery modulating cellular proliferation through feedback from acute tubular necrosis (1 patient) were the cause mechanisms, and previous studies suggest a role for these of end-stage renal disease. All seven patients were hypermolecules in experimental models of neointimal hypertensive. The mean cholesterol level was 167 mg/dL plasia [16, 19, 21] . (range 125 to 187), and the mean triglyceride level was Antibody specificities 296 mg/dL (range 93 to 516). The graft in question was
All of the antibodies used in this study are commerthe first permanent access in all patients. One patient cially available (Table 1) . We have previously docuhad a previous cuffed catheter. The average time bemented the specificity of the anticytokine antibodies with tween graft placement and the surgical revision (time of peptide inhibition studies for the anti-PDGF-B antispecimen acquisition) was 37 months (8 to 66 months).
body, Western blots against cell extracts known to exThe average number of thrombotic episodes in this copress bFGF, for the anti-bFGF antibody, and a comparihort was three (range 1 to 6).
son of the staining patterns with two other VEGF antibodies, for our anti-VEGF antibody [22] .
Collection of samples
Discarded segments from the venous end of 11 PTFE Immunohistochemistry grafts were collected at the time of graft revision surgery A standard automated streptavidin biotin technique of thrombosed PTFE dialysis grafts. While we tried to was used (Ventana 320ES automated immunostainer, obtain upstream graft (just before the graft-vein anastoTucson, AZ, USA). Briefly, following deparaffinization mosis) and downstream (proximal) vein (beyond the and hydration, slides were washed and underwent protegraft-vein anastomosis and towards the heart) in each ase digestion (if required for a particular primary antiof the samples, this was not always possible because of body). Slides were then incubated with the primary antithe surgical constraints associated with refashioning the body for 32 minutes with the biotinylated secondary thrombosed graft. Excised tissue was fixed in formalin antibody blend (anti-rabbit Ig, anti-mouse IgG, and antiand then embedded in paraffin using standard techmouse IgM) for eight minutes and with the streptavidin/ niques. The number of tissue blocks from each sample horseradish peroxidase for eight minutes (Table 1 ). All varied from one to six. This was dependent on the incubations were performed at 37ЊC with constant moveamount of graft with attached vein that individual surment and with appropriate washes between each step. geons were able to obtain at the time of graft revision
The slides were then developed with a diaminobenzidine/ surgery. Each block was 3 to 4 mm in thickness. Normal hydrogen peroxide mixture for four minutes, countervein of similar caliber to veins in the forearm was obstained with hematoxylin, dehydrated with graduated alcohol and xylene, and mounted using a xylene-based tained at the time of multiorgan harvest. are shown in Figure 2 . Within individual specimens, separate scores were given for those samples that contained PTFE graft (upstream graft) and those that did not (downstream vein). Thus, in the Results section, when reference is made to findings at the site of upstream PTFE graft, it indicates the pattern of staining either at the graft-vein anastomosis or just before the anastomosis ( Fig. 1 , areas B and C; PTFE graft would always be present in such a sample), while findings that refer to downstream (proximal) vein indicate the pattern of staining in the venous segment beyond the graft and towards the heart (Fig. 1 , area A; no PTFE graft would be present in these samples). Each parameter analyzed (whether cell type, cytokine, or matrix protein) was assessed at a number of different sites within the specimen. For example, VEGF expression was scored within (1) the adventitial vessels overlying upstream graft and downstream and (4) stromal cells (smooth muscle cells/myofibroblasts) and microvessels within the neointima of both upstream graft and downstream vein. medium. A brown color indicated a positive stain. Negative controls were performed on each run by substituting Statistical analyses the primary antibody with a relevant nonspecific immunoAlthough this study was designed essentially as a deglobulin (rabbit polyclonal or mouse monoclonal). In adscriptive analysis, a statistical analysis comparing the exdition, positive control tissue (gut, lymph node, and spleen) pression of specific cell types, cytokines, and matrix prowas used to document the efficacy of each antibody. teins in the upstream graft ( Fig. 1 , areas B and C and Histologic scoring Table 2 ) was performed in comparison with the downstream vein (Fig. 1 , area A and Table 2 ). This comparison The degree of neointimal hyperplasia on hematoxylin was only made between the same parameter at different and eosin (H and E) sections and the intensity of immusites. This was done to ensure that the semiquantitative nohistochemical staining for the different cell types, cytoscore at the two different sites indicated the same level of kines, and matrix/structural proteins listed above was expression (for example, in the comparison of adventitial scored by two observers (S.C.H. and P.R.C.) on a semiangiogenesis in upstream graft vs. downstream vein, a quantitative scoring scale from 0 (minimal VNH or no score of 2ϩ indicated the same number of microvessels expression) to 5ϩ (significant VNH or intense expresat the two sites). The expression of the same cellular sion). Most of our tissue samples had more than one phenotype at different sites in the specimens was also section. Therefore, the section with the maximum score compared, but only when the quantitation of the scoring was used for further analyses. Representative examples showing the range of staining intensity in these studies system was identical (for example, adventitial angiogen- esis was compared with neointimal angiogenesis, because the one cell-layer-thick intima (thin arrows) and the three a score of 2ϩ at either of these sites indicates the same to four cell-layer-thick media (thick arrows; Table 2 ). number of microvessels). Comparisons were never made Cellular phenotypes.
(1) SMA was present in the mewhen the scoring system for the parameters was not dia of normal vein (between thin arrows, Fig. 3c ). (2) the same (for example, PDGF in adventitial vessels was vWF was expressed by the endothelial cell layer (Fig. never compared to bFGF in adventitial vessels, as a score 3b) and occasionally by vessels within the adventitia. of 2ϩ for bFGF indicates a different level of staining as (3) There were no Ki-67-positive proliferating cells in compared with a 2ϩ score for PDGF). Statistical analynormal vein. (4) Macrophages were rarely present within ses were performed using analysis of variance (ANOVA the adventitia of normal vein. (5) Desmin was present with Tukey's test, SigmaPlot). A P value of Ͻ0.05 was within the venous media only. Also note the pronounced considered significant. difference in size between normal vein and the samples from dialysis patients with venous stenosis (Fig. 3 c com-RESULTS pared with d).
Normal vein
Cytokines.
(1) bFGF was present within the venous media and intima. (2) PDGF was present within the Hematoxylin and eosin. Normal vein of a similar caliber to our stenotic samples is shown in Figure 3a . Note venous media. (3) VEGF was present within the venous layering both sides of the graft (Fig. 4 e, g ). In addition, Mφ were also present in smaller numbers within the 
45). von Willebrand factor (endothelial cells).
This endomedia and intima on smooth muscle cells and endothelial thelial cell marker identified microvessels, both within cells. the adventitia (upstream graft ϭ 2.86 Ϯ 0.34, downMatrix proteins. Tenascin, collagen IV, and fibronecstream vein ϭ 2.60 Ϯ 0.25) and neointima (upstream tin were present within adventitial vessels in normal vein. graft ϭ 1.29 Ϯ 0.42, downstream vein ϭ 1.80 Ϯ 0.58; Fibronectin was also present within the intima of normal Fig. 4 c, d ). vein.
Ki-67 (proliferating cells).
The largest number of Ki 67-positive cells were in areas of microvessel formation Venous stenosis specimens (Table 2) (on endothelial and smooth muscle cells) within the ad-
Upstream PTFE graft (H and E).
A number of distinct ventitia (upstream graft ϭ 2.13 Ϯ 0.48, downstream vein ϭ layers were visible on these sections (Fig. 4a) . These 2.60 Ϯ 0.25). Ki-67-positive cells were also present within included: (1) a false adventitia on the outside of the stromal-type cells in the neointima (upstream graft ϭ graft that often had very prominent angiogenesis; (2) a 2.00 Ϯ 0.38, downstream vein ϭ 1.17 Ϯ 0.31; Fig. 4 
d, f). macrophage and foreign body giant cell layer on both
Some microvessels within the neointima demonstrated the adventitial and luminal sides of the PTFE graft; (3) active angiogenesis (identified by double-labeling studies PTFE graft material infiltrated by occasional mononufor Ki-67 and vWF; Fig. 4d ). clear cells; (4) a prominent region of venous neointimal Cytokines (Table 2 ) hyperplasia (extent of arrow in Fig. 4a ; mean score Ϯ SEM ϭ 1.89 Ϯ 0.35) comprising smooth muscle cells and Basic fibroblast growth factor. bFGF was present on myofibroblasts, ECM components, and a large number neointimal stromal (smooth muscle cells/myofibroblasts)-of microvessels; and finally (5) in many cases, an endotype cells (upstream graft ϭ 2.14 Ϯ 0.40, downstream vein ϭ 1.40 Ϯ 0.40) and neointimal microvessels (upthelial layer that lined the neointima. Fig. 5c ) and mi-0.4). bFGF was also present on the adventitial vessels overlying both upstream graft (2.25 Ϯ 0.37; Fig. 4g ) and crovessels (upstream graft ϭ 4.86 Ϯ 0.14; downstream vein ϭ 3.50 Ϯ 1.19) within the neointima. Fibronectin downstream vein (2.40 Ϯ 0.40). There was intense staining for bFGF by the macrophage giant cell layer lining was present on the macrophage and foreign body giant cell layer lining upstream graft (1.5 Ϯ 0.96) and also both sides of the graft (3.13 Ϯ 0.30; Fig. 4g ) and by infiltrating mononuclear cells within the graft (3.17 Ϯ appeared to be secreted into the actual matrix of the graft material. 0.40). In some samples, the PTFE graft itself stained strongly for bFGF (Fig. 4g) , suggesting that this cytokine Laminin. Laminin was expressed by adventitial vessels in both upstream graft (3.88 Ϯ 0.13) and downstream might be diffusing through the interstices of the graft.
Platelet-derived growth factor. PDGF was present in vein (3.67 Ϯ 0.21; Fig. 5d ). Laminin was present within the neointima of upstream graft (2.43 Ϯ 0.30) and downadventitial vessels in both upstream graft (1.88 Ϯ 0.40) and downstream vein (2.17 Ϯ 0.48). There was strong stream vein (2.67 Ϯ 0.33), and in microvessels within the neointima (upstream graft ϭ 3.67 Ϯ 0.21, downstream staining for PDGF by the macrophage giant cell layer on both sides of the graft (2.38 Ϯ 0.42) and by macrophages vein ϭ 3.67 Ϯ 0.33). Laminin was also present in stromal elements of the neointima, especially at the site of what that had infiltrated into the graft material (1.50 Ϯ 0.54). Within the region of VNH, PDGF was present on stroappeared to be needle track injuries. mal cells (upstream graft ϭ 1.88 Ϯ 0.52; downstream Statistical analyses vein ϭ 3.00 Ϯ 0.71; Fig. 4h ) and microvessels (upstream Quantitative results are presented in Table 2 . VNH graft ϭ 1.50 Ϯ 0.33; downstream vein ϭ 2.80 Ϯ 1.48).
was more pronounced in downstream vein as compared Vascular endothelial growth factor. VEGF was preswith upstream graft by hematoxylon and eosin analysis ent in the adventitial vasculature overlying both up-(P ϭ 0.005). Within this downstream lesion, there was stream graft (3.00 Ϯ 0.42) and downstream vein (4.00 Ϯ greater expression of the smooth muscle cell marker 0.71). VEGF was also present in the macrophage/giant SMA actin as compared with upstream graft (P ϭ 0.004). cell layer lining both sides of the graft (2.75 Ϯ 0.56) Finally, there was significantly more angiogenesis in the and in macrophages that had infiltrated into the graft adventitia of upstream graft as compared with the neomaterial. As for bFGF and PDGF, VEGF was present intima at the same site (P ϭ 0.038; Table 2 ). in stromal-type cells (upstream graft ϭ 2.71 Ϯ 0.42;
Because of the small number of samples available, we downstream vein ϭ 2.50 Ϯ 0.30) and microvessels (upcould have missed important differences as a result of stream graft ϭ 3.33 Ϯ 0.42; downstream vein ϭ 3.50 Ϯ inadequate power. Therefore, possible trends were iden-0.87) within the venous neointima.
tified (mean separation Ͼ0.5) toward differences between Matrix and structural proteins (Table 2) the upstream graft and downstream vein (Table 2) . A brief summary of these trends between upstream graft Tenascin. Tenascin was present within adventitial vessels overlying both upstream graft (2.00 Ϯ 0.84) and downand downstream vein is given below. Cellular phenotypes. Desmin had stronger expression stream vein (2.25 Ϯ 0.48; Fig. 5a ). Tenascin appeared to be secreted by the macrophage/giant cell layer lining on the abluminal side of downstream vein as compared with downstream graft. Macrophages were generally both sides of the graft. Within the neointima, tenascin was present within the ECM in upstream graft (3.20 Ϯ more prominent within the adventitia of upstream graft. Ki-67 (proliferating cells) were present in the greatest 0.20) and downstream vein (2.75 Ϯ 0.48). While the expression of tenascin appeared to be more on the abluminumbers in the adventitia and neointima of the upstream graft as compared with the downstream vein. There were nal surface in some samples (Fig. 5a) , this was not consistent throughout the study. Tenascin was also expressed relatively more microvessels in the neointima of downstream vein as compared to upstream graft. by microvessels within the neointima. The hypertrophied venous media had strong expression of tenascin (3.25 Ϯ Cytokines. bFGF was increased within the neointima (stromal cells and microvessels) of upstream graft as 0.63).
Collagen IV. Collagen IV was expressed by adventitial compared with downstream vein. PDGF, in contrast, was increased within the neointima (stromal cells and vessels in both upstream graft (2.50 Ϯ 0.87) and downstream vein (3.20 Ϯ 0.20; Fig. 5b ). Collagen IV was also microvessels) of downstream vein. VEGF was increased in the adventitial vessels of downstream vein as compresent within the neointima of upstream graft (3.00 Ϯ 0.45) and downstream vein (3.00 Ϯ 0.00) and in microvespared with those of upstream graft. Matrix and structural proteins. Fibronectin was insels within the neointima (upstream graft ϭ 3.00 Ϯ 0.58; downstream vein ϭ 3.00 Ϯ 0.58).
creased in the adventitial vessels of downstream vein and within the neointima (stromal cells and microvessels) of Fibronectin. Fibronectin was expressed by adventitial vessels in both upstream graft (3.33 Ϯ 0.49) and downupstream graft. Collagen was increased in the adventitial vessels of downstream vein. stream vein (4.17 Ϯ 0.40; Fig. 5c ). Fibronectin was also
DISCUSSION
within the intima of our samples at an earlier time point has gone unrecognized by the present study. While apDespite the clinical importance of hemodialysis vascuproximately 50 to 75% of stromal-type cells within the lar access dysfunction, there has been little research on neointima were positive for SMA, this was not the case the pathogenesis of venous neointimal hyperplasia in the for desmin, which was present on less than 10% of neospecific setting of dialysis access grafts. Therefore, the intimal cells (mainly at the abluminal border). In their expression of specific cell types, cytokines, and matrix model of coronary venous grafting, Shi et al [18] and proteins in dialysis access specimens with venous stenosis O'Brien et al [19] have suggested that SMA-positive, were documented in an attempt to understand better desmin-negative cells are likely to be adventitial fibrothe pathogenesis of this lesion. We believe that this is blasts that have transformed into smooth muscle-type a first step toward the development of more effective cells and have migrated into the neointima. This is an measures for the prevention and treatment of this condiimportant concept as it suggests that the changes in the tion.
adventitia could be influencing final luminal stenosis (discussed later in this article). We plan on closely examining Initiating events this theory in a large animal model of VNH (abstract; An important initiating event in the pathogenesis of Roy-Chaudhury et al, J Am Soc Nephrol 9:181, 1998). VNH is thought to be hemodynamic stress (specifically a low shear stress [23, 24] caused by turbulence and Adventitial remodeling compliance mismatch), which then activates (alters the This study clearly documents the presence of cellular phenotype of) smooth muscle cells and endothelial cells proliferation, ECM protein accumulation, and cytokine [25] at the graft-vein anastomosis. Our study suggests a expression within the adventitia of both upstream graft second potential initiating factor, namely the macroand downstream vein. In particular, there was increased phage giant cell layer that lines both sides of PTFE graft microvessel formation in the adventitia surrounding upand has intense expression of all three cytokines disstream graft as compared with the neointima at the same cussed in this article (especially bFGF; Fig. 4g ). We besite. These findings are in keeping with recent studies lieve that PTFE graft material functions as a foreign that indicate that activation and migration of adventitial body (perhaps made worse by the repeated punctures cell types are an important determinant of vascular stefor dialysis), which attracts activated macrophages to the nosis [18, 19] . Specifically, some studies suggest that adsite of the lesion. These activated macrophages then verse adventitial remodeling (constriction) could be as produce cytokines such as bFGF, PDGF, and VEGF, important as neointimal volumes in determining final which are known to cause smooth muscle cell, fibroblast, luminal stenosis [26] . With regard to possible clinical and endothelial cell differentiation, proliferation, and application, therefore, our study suggests that therapeumigration [11] .
tic intervention in experimental models should be targeted at both the adventitia and the neointima. Table 2 demonstrates the presence of active cellular Angiogenesis proliferation within stromal-type cells in the neointima.
Smooth muscle cell proliferation
A consistent finding in our study was the presence of There were significantly more smooth muscle cells within microvessels, both within the neointima and adventitia the neointima of downstream vein as compared with the of upstream graft and downstream vein (Fig. 4 c, d , f, g). upstream graft, which suggests a preferential migration
In addition, many of our specimens also had evidence of smooth muscle cells from the venous media of the of active endothelial and pericyte proliferation (angiodownstream vein into the neointima. Interestingly, in genesis) within microvessels in the neointima (Fig. 4 d, f ) some specimens with a large number of smooth muscle and adventitia. These results are in keeping with those cells within the venous neointima, double-staining experof Rekhter et al, who demonstrated that maximal cellular iments revealed active proliferation within endothelial proliferation occurred in vascular regions of the neoincells lining microvessels (angiogenesis, discussed later in tima [10] . Of note, microvessels have also been found this article), but not in the smooth muscle cells (Fig. 4f) , within the neointima and adventitia in coronary atherowhich formed the bulk of the neointimal lesion. This sclerosis [27] and in experimental models of coronary could be due to the fact that migration of smooth muscle stenosis [28] . The importance of neointimal and adventicells from the media, rather than in situ intimal proliferatial angiogenesis is emphasized by recent seminal studies tion, is the key driving force for VNH. An alternative that have demonstrated that both neoplastic [29, 30] and explanation could be that our samples can only provide non-neoplastic [31] tissue growth can be reduced by inhibus with a snapshot of a single time-point that is at the iting angiogenesis. Our primarily descriptive study (which end of the natural history of the disease process. Thus, examines tissue at a single time point only) unfortunately does not allow a cause and effect relationship between it is possible that active smooth muscle cell proliferation angiogenesis and neointimal hyperplasia to be identified.
the pathogenesis of VNH in dialysis access grafts. These Further studies in an experimental animal model are include cellular proliferation, microvessel formation, and needed to establish whether anti-angiogenic agents could cytokine expression (perhaps the key factor) by smooth be an effective therapeutic modality for VNH. muscle cells, endothelial cells, and macrophages, resulting in the activation and proliferation of these cell Cytokines types. Based on the results from this study, we are curPlatelet-derived growth factor and bFGF are imporrently testing specific interventions in a pig model of tant mediators of the smooth muscle cell proliferation VNH (abstract; ibid). In conclusion, we believe that vethat characterizes neointimal hyperplasia in balloon annous stenosis in PTFE dialysis grafts could be the ideal gioplasty models [13, 14] . bFGF and VEGF are also clinical target for novel locally delivered therapeutic inpotent angiogenic growth factors [32] . All three cytoterventions against neointimal hyperplasia, in view of kines were present on smooth muscle cells and on vessels, the accessibility of both the patient (on hemodialysis within the adventitia and neointima of upstream graft three times a week) and the lesion (superficially located). and downstream vein in our study. There was also intense expression of these cytokines by the macrophage giant ACKNOWLEDGMENTS cell layer lining PTFE graft (Fig. 4g) . With regard to
